Impact of oral iron dosing regimens on iron biomarkers during pregnancy: insights from the PANDA trial.

Modified oral iron regimens are increasingly used to balance iron intake, absorption, and tolerability.

改良的口服铁剂方案越来越多地被用来平衡铁的摄入、吸收和耐受性。

This study evaluated the effects of daily, alternate-day, and 3-times-weekly oral iron supplementation on iron status biomarkers in nonanaemic pregnant participants.

本研究评估了每日、隔日和每周三次口服铁剂补充对非贫血孕妇铁状态生物标志物的影响。

In the PANDA (Primary prevention of maternal Anemia to avoid preterm Delivery and other Adverse outcomes) dose-finding trial, nonanemic pregnant women were randomized to receive 200 mg of ferrous sulfate daily, on alternate days, or 3-times-weekly.

在PANDA（预防孕产妇贫血以避免早产和其他不良结果的初级预防）剂量发现试验中，非贫血孕妇被随机分配接受每日200毫克硫酸亚铁、隔日或每周三次。

Blood samples were collected at 9 to 13 and 26 to 30 weeks' gestation (N = 135 participants).

在妊娠9至13周和26至30周时收集了血液样本（N=135名参与者）。

Hepcidin and soluble transferrin receptor (sTfR) were measured by enzyme-linked immunosorbent assay, and serum iron, ferritin, transferrin, and C-reactive protein using automated biochemistry.

通过酶联免疫吸附试验测量了肝素和可溶性转铁蛋白受体（sTfR），并通过自动化生化分析测量了血清铁、铁蛋白、转铁蛋白和C反应蛋白。

Linear mixed-effects models assessed within- and between-group biomarker changes.

线性混合效应模型评估了组内和组间生物标志物的变化。

Hepcidin, ferritin, and transferrin saturation declined significantly between baseline and follow-up in all groups (P< .001). sTfR increased in the alternate-day (P = .003) and 3-times-weekly groups (P< .001), but not in the daily group (P = .084).

所有组别中，肝素、铁蛋白和转铁蛋白饱和度在基线和随访期间显著下降（P< .001）。交替日组和每周三次组的可溶性转铁蛋白受体（sTfR）增加（P = .003 和 P< .001），而每日组则没有显著增加（P = .084）。

Despite supplementation and maintenance of hemoglobin levels, 69% to 72% of women were iron deficient (ferritin <30 μg/L) at 26 to 30 weeks' gestation.

尽管进行了补充和维持血红蛋白水平，但在妊娠26至30周时，仍有69%至72%的女性铁缺乏（铁蛋白<30 μg/L）。

Iron status declined across pregnancy regardless of supplementation regimen, suggesting physiological adaptations may dominate over dosing effects.

无论补充方案如何，孕妇的铁状态在整个妊娠期间都会下降，这表明生理适应可能比剂量效应更为重要。

The absence of a significant rise in sTfR in the daily group suggests that daily dosing best meets the iron demand of pregnancy, though confirmation in larger, adequately powered studies is required.

日常组中可溶性转铁蛋白受体（sTfR）没有显著上升，这表明每日剂量最能满足妊娠期的铁需求，尽管需要在更大规模、足够统计功效的研究中进行确认。

This trial was registered at the UK trial registry as #ISRCTN12911644.

这项试验已在英国试验注册处注册，编号为#ISRCTN12911644。